Androgen Deprivation Therapy Market Report 2026

The androgen deprivation therapy market size has grown strongly in recent years. It will grow from $8.31 billion in 2025 to $8.83 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to limited treatment options for prostate cancer, reliance on conventional surgery, slow adoption of injectable therapies, low patient awareness of androgen deprivation therapy, restricted availability of advanced therapies.

The androgen deprivation therapy market size is expected to see strong growth in the next few years. It will grow to $11.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to development of novel anti-androgen drugs, increasing investment in gene and immunotherapies, rising geriatric male population, growth in specialty clinics and hospital oncology departments, integration of digital monitoring and telehealth solutions. Major trends in the forecast period include rising adoption of lhrh agonists and antagonists, increased use of combination and targeted therapies, expansion of minimally invasive surgical procedures, growing focus on patient-specific and age-based treatments, enhanced monitoring and follow-up care for prostate cancer patients.

The rising incidence of prostate cancer is anticipated to drive the growth of the androgen deprivation therapy market in the coming years. Prostate cancer develops in the prostate gland, a component of the male reproductive system that produces seminal fluid. Its incidence is increasing primarily due to extended life expectancy, as advancing age significantly elevates the risk of developing the disease. Androgen deprivation therapy (ADT) is a key treatment approach for prostate cancer, designed to reduce androgen levels that stimulate tumor growth. It is commonly used in advanced or metastatic stages to slow disease progression. For instance, in January 2025, according to a report released by Prostate Cancer UK, a UK-based organization focused on prostate cancer research, awareness, and support, the number of prostate cancer diagnoses in England rose from 50,751 cases in 2022 to 55,033 cases in 2023, highlighting a notable increase in annual incidence. Therefore, the growing incidence of prostate cancer is contributing to the expansion of the androgen deprivation therapy market.

Major companies operating in the androgen deprivation therapy (ADT) market are concentrating on the development of advanced treatment options, such as oral androgen receptor inhibitors (ARIs), to offer more convenient, well-tolerated, and effective therapies for prostate cancer patients. Oral ARIs are targeted medications that directly inhibit androgen receptor activity in prostate cancer cells, thereby preventing tumor growth without the need for frequent clinic-based hormone-suppressing injections. For instance, in June 2025, Bayer AG, a Germany-based multinational pharmaceutical company, received approval from the US Food and Drug Administration for Nubeqa (darolutamide), an oral ARI used in combination with ADT for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Developed to enhance clinical outcomes and patient quality of life, Nubeqa blocks androgen receptor signaling with high binding affinity, exhibits minimal penetration across the blood-brain barrier to reduce central nervous system side effects, and demonstrated a 46% reduction in the risk of radiographic progression or death compared with placebo plus ADT, as shown in the Phase III ARANOTE trial.

In February 2025, Tempus, a US-based health technology company, entered into a partnership with Artera to commercialize Artera’s advanced prostate cancer risk assessment tool, the ArteraAI Prostate Test. This collaboration is intended to improve the precision of cancer prognosis by leveraging artificial intelligence to support more informed clinical decision-making. Consequently, ArteraAI’s advanced digital pathology test, which is included in the NCCN guidelines, will help identify patients with intermediate localized prostate cancer who are most likely to benefit from short-term androgen deprivation therapy. Artera is a US-based digital health company.

Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.

North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the androgen deprivation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the androgen deprivation therapy market by increasing the cost of imported drugs, surgical instruments, and radiopharmaceuticals. Segments such as LHRH agonists, antagonists, and targeted therapies are most affected, particularly in regions like North America and Asia-Pacific where import dependency is high. The tariffs have raised treatment costs and disrupted supply chains, but they have also incentivized local drug manufacturing, encouraged domestic production of surgical tools, and fostered innovation in cost-effective therapies.

The androgen deprivation therapy market research report is one of a series of new reports that provides androgen deprivation therapy market statistics, including androgen deprivation therapy industry global market size, regional shares, competitors with a androgen deprivation therapy market share, detailed androgen deprivation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the androgen deprivation therapy industry. This androgen deprivation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Androgen deprivation therapy is a treatment approach that lowers or suppresses the activity of male hormones in the body to restrict the growth of hormone-dependent cells. These hormones are essential to many physiological processes, and reducing their levels can significantly affect cellular activity and biological responses.

The main types of androgen deprivation therapy include medication, surgery, and other approaches. Medication-based ADT involves the use of drugs to decrease or block androgen production. It is available through different routes of administration, including injectable and oral forms, and is used across various patient groups such as men aged 40-60, men aged 61-75, and men above 75. This therapy is primarily applied in the treatment of prostate cancer and other conditions and is utilized by end users including hospitals, specialty clinics, and others.

The androgen deprivation therapy market consists of revenues earned by entities by providing services such as hormonal assessment, monitoring services, telehealth consultations, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The androgen deprivation therapy market also includes sales of hormone monitoring test kits, implantable hormone delivery systems, topical hormone regulation products, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.